Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $8.37, for a total transaction of $16,740.00. Following the transaction, the chief executive officer now directly owns 14,605,662 shares of the company’s stock, valued at $122,249,390.94. The trade was a 0.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $9.09, for a total transaction of $18,180.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.77, for a total transaction of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total value of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Price Performance

Shares of NASDAQ ZYXI opened at $7.80 on Friday. The business has a 50-day simple moving average of $8.23 and a two-hundred day simple moving average of $8.88. The company has a market cap of $248.43 million, a PE ratio of 52.00 and a beta of 0.53. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77.

Zynex (NASDAQ:ZYXI) last issued its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Zynex’s revenue for the quarter was up .1% on a year-over-year basis. As a group, equities analysts expect that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Zynex

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Zynex by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock valued at $14,684,000 after acquiring an additional 6,097 shares during the period. Hotchkis & Wiley Capital Management LLC raised its holdings in Zynex by 24.7% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after acquiring an additional 147,770 shares during the last quarter. Geode Capital Management LLC lifted its position in Zynex by 6.7% during the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock worth $3,473,000 after buying an additional 26,774 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Zynex by 66.5% during the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after acquiring an additional 118,615 shares during the period. Finally, Royce & Associates LP raised its stake in Zynex by 9.2% during the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after purchasing an additional 21,781 shares during the period. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright boosted their price objective on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Royal Bank of Canada decreased their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.